Wissenschaftliche Arbeiten

Doç. Dr. Özgür Açıkgöz

78 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

    Cerrahpasa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26082 Frei zugänglicher VolltextQuelle: OpenAlex

  2. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Frei zugänglicher VolltextQuelle: OpenAlex

  5. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Frei zugänglicher VolltextQuelle: OpenAlex

  6. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Frei zugänglicher VolltextQuelle: OpenAlex

  8. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  9. Investigation of Predictive and Prognostic Factors in Metastatic Renal Cell Carcinoma (mRCC) Patients Receiving First-line Treatment: A Retrospective Single-center Experience

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.78942 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166326 PMID 42652730 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Claudin 18.2, IDH1, and neutrophil-to-lymphocyte ratio as prognostic biomarkers in unresectable pancreatic ductal adenocarcinoma receiving first-line chemotherapy

    Biomolecules and Biomedicine, 2026

    DOI 10.17305/bb.2026.14093 PMID 41954483 Frei zugänglicher VolltextQuelle: OpenAlex

  12. A Composite Histopathologic Invasion Score Predicts Lymph Node Metastasis in Gastric Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176509 PMID 42739515 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    Medicina, 2025

    DOI 10.3390/medicina61030380 PMID 40142191 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  14. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14072264 PMID 40217714 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  15. The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy

    Diagnostics, 2025

    DOI 10.3390/diagnostics15081048 PMID 40310425 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14092937 PMID 40363968 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  17. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

    Ege Tıp Dergisi, 2025

    DOI 10.19161/etd.1569835 Frei zugänglicher VolltextQuelle: OpenAlex

  18. The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186536 PMID 41010740 Frei zugänglicher VolltextQuelle: OpenAlex

  19. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

    Clinical Lung Cancer, 2025

    DOI 10.1016/j.cllc.2025.07.015 PMID 40813186 2 Zitationen (Europe PMC) Quelle: OpenAlex

  20. The Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    2025

    DOI 10.20944/preprints202508.0265.v1 Frei zugänglicher VolltextQuelle: ORCID

  21. The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy

    2025

    DOI 10.20944/preprints202503.1873.v1 Frei zugänglicher VolltextQuelle: ORCID

  22. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes- Single-Center Experience

    2025

    DOI 10.20944/preprints202503.0015.v1 Frei zugänglicher VolltextQuelle: ORCID

  23. Prognostic Value of Claudin 18.2, Isocitrate Dehydrogenase-1, and Neutrophil-to-Lymphocyte Ratio in Unresectable Pancreatic Ductal Adenocarcinoma

    2025

    DOI 10.20944/preprints202502.1220.v1 Frei zugänglicher VolltextQuelle: ORCID

  24. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Quelle: OpenAlex

  25. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241241004 PMID 38613329 Frei zugänglicher VolltextQuelle: OpenAlex

  26. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 Zitationen (Europe PMC) Quelle: OpenAlex

  27. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

    Current Problems in Cancer, 2024

    DOI 10.1016/j.currproblcancer.2024.101102 PMID 38735211 2 Zitationen (Europe PMC) Quelle: OpenAlex

  28. Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024

    DOI 10.32708/uutfd.1515582 Frei zugänglicher VolltextQuelle: OpenAlex

  29. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2314830 PMID 38351652 2 Zitationen (Europe PMC) Quelle: OpenAlex

  30. Torasik Rayoterapi Sonrası Gelişen Radyasyon Pnömoniti Hastalarında Prognostik ve Prediktif Faktörlerin Analizi: Retrospektif Tek Merkez Deneyimi

    Ege Tıp Bilimleri Dergisi, 2024

    DOI 10.33713/egetbd.1527615 Frei zugänglicher VolltextQuelle: OpenAlex

  31. Prognostic And Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    2024

    DOI 10.20944/preprints202412.2244.v1 Frei zugänglicher VolltextQuelle: ORCID

  32. Real-World Outcomes Of Lu-177 PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Experience

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3365105/v1 Frei zugänglicher VolltextQuelle: OpenAlex

  33. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

    Biomolecules and Biomedicine, 2023

    DOI 10.17305/bb.2023.9253 PMID 37289436 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  34. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

    Medicine, 2023

    DOI 10.1097/md.0000000000033432 PMID 37058061 14 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  35. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Chemotherapy and Pharmacology, 2023

    DOI 10.1007/s00280-023-04592-x PMID 37773537 8 Zitationen (Europe PMC) Quelle: OpenAlex

  36. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

    International Immunopharmacology, 2023

    DOI 10.1016/j.intimp.2023.110947 PMID 37742369 5 Zitationen (Europe PMC) Quelle: OpenAlex

  37. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

    Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2023

    DOI 10.26650/iuitfd.1211556 Frei zugänglicher VolltextQuelle: OpenAlex

  38. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

    Journal of Gastrointestinal Cancer, 2023

    DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 Zitation (Europe PMC) Quelle: OpenAlex

  39. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.00187 Frei zugänglicher VolltextQuelle: OpenAlex

  40. Erken Evre Triple Negatif Meme Kanserinde Sağkalım Sonuçları ve Prognostik Faktörler: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2023

    DOI 10.32708/uutfd.1356458 Frei zugänglicher VolltextQuelle: OpenAlex

  41. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

    Journal of Chemotherapy, 2023

    DOI 10.1080/1120009x.2023.2247207 PMID 37599454 2 Zitationen (OpenAlex) Quelle: OpenAlex

  42. Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

    DOI 10.55730/1300-0144.5659 PMID 38031948 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  43. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1100 Frei zugänglicher VolltextQuelle: OpenAlex

  44. Impact of systemic inflammatory markers in patients with ALK -positive non-small cell lung cancer treated with crizotinib

    Pulmonology, 2022

    DOI 10.1016/j.pulmoe.2022.11.006 PMID 36564237 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  45. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

    Breast Care, 2022

    DOI 10.1159/000524446 PMID 36684400 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  46. Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001389 PMID 36206103 11 Zitationen (Europe PMC) Quelle: ORCID

  47. Toraks Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1073 Frei zugänglicher VolltextQuelle: OpenAlex

  48. Does Platelet Count Affect Survival Outcomes in Patients with Malignant Pleural Mesothelioma?

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2021.09122 Quelle: OpenAlex

  49. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.2017952 PMID 34894960 3 Zitationen (Europe PMC) Quelle: OpenAlex

  50. P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.457 Frei zugänglicher VolltextQuelle: OpenAlex